These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34198132)

  • 61. Characterizing the social support and functioning of a low-threshold medication for opioid use disorder treatment cohort at intake.
    Oles W; Alexander M; Kumar N; Howell B; O'Connor PG; Madden LM; Barry DT
    BMC Psychiatry; 2022 Apr; 22(1):236. PubMed ID: 35366844
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of COVID-19 on MOUD retention in a sample of rural primary care patients: A secondary analysis of electronic health records.
    Calhoun S; Guo H; Fei Z; Lin C; Clingan SE; Zhu Y; Mooney LJ; Hser YI
    Drug Alcohol Depend Rep; 2024 Sep; 12():100276. PubMed ID: 39286538
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Higher perceived stress during admission is associated with shorter retention in short-term residential substance use disorder treatment.
    Ware OD; Sacco P; Cagle JG; Frey JJ; Wagner FA; Wimberly AS; Gyebi-Foster B; Diaz M; Peters K; Zemore SE
    Addict Behav Rep; 2023 Dec; 18():100502. PubMed ID: 38170055
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Disparities in Opioid Use Disorder Treatment Admissions.
    Mallow PJ; Mercado M; Topmiller M
    J Health Econ Outcomes Res; 2020; 7(1):85-93. PubMed ID: 32685601
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network.
    Wu LT; Ling W; Burchett B; Blazer DG; Shostak J; Woody GE
    Subst Abuse Rehabil; 2010 Dec; 2010(1):13-22. PubMed ID: 21709734
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Disparities in opioid treatment access and retention among women based on pregnancy status from 2006 to 2017.
    Khachikian T; Amaro H; Guerrero E; Kong Y; Marsh JC
    Drug Alcohol Depend Rep; 2022 Mar; 2():. PubMed ID: 35369381
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of age and opioid agonist treatment on substance use treatment completion in the United States.
    van den Berk Clark C; Pickard JG; Drallmeier T
    Aging Ment Health; 2022 Jun; 26(6):1295-1302. PubMed ID: 33999741
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Admission Practices And Cost Of Care For Opioid Use Disorder At Residential Addiction Treatment Programs In The US.
    Beetham T; Saloner B; Gaye M; Wakeman SE; Frank RG; Barnett ML
    Health Aff (Millwood); 2021 Feb; 40(2):317-325. PubMed ID: 33523744
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Improving Outcomes for People With Injection Drug-related Endocarditis: Are Medications for Opioid Use Disorder Enough?
    Kimmel SD; Del Rio C
    J Addict Med; 2020; 14(4):280-0. PubMed ID: 31634203
    [No Abstract]   [Full Text] [Related]  

  • 70. "Medications for opioid use disorder during the war in Ukraine: a more comprehensive view on the government response-Authors' reply".
    Bromberg DJ; Madden LM; Meteliuk A; Ivasiy R; Galvez de Leon SJ; Klyucharyov K; Altice FL
    Lancet Reg Health Eur; 2023 Mar; 26():100583. PubMed ID: 36747509
    [No Abstract]   [Full Text] [Related]  

  • 71. Correction to: Racial/Ethnic Disparities in Opioid-Related Mortality in the USA, 1999-2019: the Extreme Case of Washington DC.
    Kiang MV; Tsai AC; Alexander MJ; Rehkopf DH; Basu S
    J Urban Health; 2021 Dec; 98(6):833. PubMed ID: 34799823
    [No Abstract]   [Full Text] [Related]  

  • 72. Corrigendum to "Age disparities in six-month treatment retention for opioid use disorder" [Drug Alcohol Depend. 213 (2020) 108130].
    Mintz CM; Presnall NJ; Sahrmann JM; Borodovsky JT; Glaser PEA; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2020 Nov; 216():108312. PubMed ID: 33007704
    [No Abstract]   [Full Text] [Related]  

  • 73. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
    Hollander MAG; Chang CH; Douaihy AB; Hulsey E; Donohue JM
    Drug Alcohol Depend; 2021 Oct; 227():108927. PubMed ID: 34358766
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
    Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
    N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association Between Patient-Level Factors and Positive Treatment Response Among Individuals With a Psychostimulant Use Disorder: A Cross-Sectional Study.
    Abulez D; Brown CC; Cucciare MA; Hayes CJ
    Subst Use; 2024; 18():29768357241274483. PubMed ID: 39420915
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Racial and Ethnic Disparities in Take-Home Methadone Use for Medicare Beneficiaries With Opioid Use Disorder.
    Choi S; Zhang Y; Unruh MA; McGinty EE; Jung HY
    JAMA Netw Open; 2024 Aug; 7(8):e2431620. PubMed ID: 39212993
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study.
    Hayes CJ; Raciborski RA; Martin BC; Gordon AJ; Hudson TJ; Brown CC; Pro G; Cucciare MA
    J Subst Use Addict Treat; 2024 Nov; 166():209461. PubMed ID: 39067770
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review.
    Chladek JS; Chui MA
    Front Public Health; 2024; 12():1377193. PubMed ID: 38803812
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effect of a pilot brief educational intervention on preferences regarding treatments for opioid use disorder.
    Irani E; Macleod C; Slat S; Kehne A; Madden E; Jaffe K; Bohnert A; Lagisetty P
    Drug Alcohol Depend Rep; 2024 Jun; 11():100235. PubMed ID: 38737490
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.